Cindy Berthelot is a Dermatology physician affiliated with Houston Institute for Clinical Research. OpenAlex indexes 17 publications with 369 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2565 Bay Area Blvd
Houston, TX 770581521
Telephone
281-480-7272Registry record last updated 27 Feb 2013.
Industry payments
25 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Organon LLCProgram year20252 payments
- Ortho Dermatologics, a division of Bausch Health US, LLCProgram year20251 payment
- Arcutis Biotherapeutics, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
37.3%Tetracycline-class Drug12.2%Doxycycline Hyclate100%Part D≥16 patientsAzole Antifungal10.2%Ketoconazole100%Part D≥23 patients+ 3 more classes in this area
Respiratory
24.6%RNA Synthetase Inhibitor Antibacterial24.6%Mupirocin100%Part D≥75 patientsSensory organs
19.3%Corticosteroid19.3%Betamethasone Dipropionate43%Clobetasol Propionate40%Hydrocortisone17%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Poor prognosis in non-Caucasian patients with early-onset mycosis fungoides
Journal of the American Academy of Dermatology
2008 - CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate
Journal of the American Academy of Dermatology
2008
Similar KOLs
Other experts from the same institution or the same specialty.
Daniel Carrasco, MD
Houston Institute for Clinical Research
Frank Lanza, MD
Houston Institute for Clinical Research
Suzanne Bruce, MD
Houston Institute for Clinical Research
Frank Wellborne, DO
Houston Institute for Clinical Research
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”